This risk reduction was in agreement with an in vitro assay which showed that the del allele decreased the transcriptional activity of NFKB1, thereby truncating its role in promoting inflammation, which in turn led to the decreased prostate cancer risk [21]. This evidence concerns the gene NFKB1 and prostate carcinoma.